Search
Innate Immunotherapeutics chief executive Simon Wilkinson.

NZ biotech chooses Australia for IPO

Perth based stockbroking firm Patersons Securities is punting on investors’ emerging appetite for biotech stocks, agreeing to underwrite New Zealand biopharmaceutical company Innate Immunotherapeutics’s $16.5 million initial public offering.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

BNIQ sponsored byBreast Cancer Research Centre

Corporate finance employees

5th↑BDO22
6th↑Argonaut16
7th↑Patersons SecuritiesNFP
8th↑Hartleys11
9th-Regency CorporateNFP
81 corporate finance ranked by staff in corporate finance area (WA)

Revenue

58th-Ross North Group$73.7m
59th↑Patersons Securities$73.4m
61st↓OrontideNFP
62nd↓Kerman Contracting$60.0m
113 private companies - large ranked by revenue most recent financial year

Client advisers

1st-Patersons SecuritiesNFP
2nd-Hartleys50
3rd-Euroz Securities37
4th-Bell Potter Securities31
5th↑Macquarie Group29
20 stockbrokers ranked by number of client advisers in WA

Number of Employees

Corporate Finance

BNiQ Disclaimer